Is IMVT or BNTX more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% BioNTech -44.39% -5.30% -4.62%

Does the media favor IMVT or BNTX?

In the previous week, BioNTech had 2 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for BioNTech and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat BioNTech's score of 1.38 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMVT or ROIV?

In the previous week, Roivant Sciences had 8 more articles in the media than Immunovant. MarketBeat recorded 12 mentions for Roivant Sciences and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Roivant Sciences' score of 1.59 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IMVT or INSM more profitable?

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Insmed -144.44% -130.11% -51.57%

Does the media refer more to IMVT or INSM?

In the previous week, Insmed had 21 more articles in the media than Immunovant. MarketBeat recorded 25 mentions for Insmed and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Insmed's score of 1.22 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 18 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or MRNA more profitable?

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Moderna -143.55% -26.64% -19.32%

Does the media favor IMVT or MRNA?

In the previous week, Moderna had 15 more articles in the media than Immunovant. MarketBeat recorded 19 mentions for Moderna and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Moderna's score of 0.57 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Moderna 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$33.62 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$33.67 +0.05 (+0.16%)

As of 06/12/2026 07:48 PM Eastern

Compare

IMVT vs. SLNO, BNTX, ROIV, INSM, and MRNA

Should you buy Immunovant stock or one of its competitors? MarketBeat compares Immunovant with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunovant include Soleno Therapeutics (SLNO), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Moderna (MRNA). These companies are all part of the "medical" sector.

How does Immunovant compare to Soleno Therapeutics?

Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immunovant currently has a consensus target price of $37.33, indicating a potential upside of 11.05%. Soleno Therapeutics has a consensus target price of $76.67, indicating a potential upside of 44.63%. Given Soleno Therapeutics' higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

In the previous week, Immunovant had 4 more articles in the media than Soleno Therapeutics. MarketBeat recorded 4 mentions for Immunovant and 0 mentions for Soleno Therapeutics. Immunovant's average media sentiment score of 1.65 beat Soleno Therapeutics' score of 0.94 indicating that Immunovant is being referred to more favorably in the media.

Company	Overall Sentiment
Immunovant	Very Positive
Soleno Therapeutics	Positive

Soleno Therapeutics has a net margin of 33.70% compared to Immunovant's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Soleno Therapeutics	33.70%	22.85%	18.25%

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, suggesting that its share price is 322% less volatile than the broader market.

Summary

Soleno Therapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

Immunovant (NASDAQ:IMVT) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Immunovant has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
BioNTech	$3.25B	7.05	-$1.29B	-$5.88	N/A

In the previous week, BioNTech had 2 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for BioNTech and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat BioNTech's score of 1.38 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioNTech	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
BioNTech	-44.39%	-5.30%	-4.62%

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Immunovant presently has a consensus price target of $37.33, indicating a potential upside of 11.05%. BioNTech has a consensus price target of $129.56, indicating a potential upside of 43.10%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BioNTech beats Immunovant on 10 of the 16 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Immunovant (NASDAQ:IMVT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Immunovant has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

In the previous week, Roivant Sciences had 8 more articles in the media than Immunovant. MarketBeat recorded 12 mentions for Roivant Sciences and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Roivant Sciences' score of 1.59 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

47.1% of Immunovant shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Immunovant presently has a consensus price target of $37.33, indicating a potential upside of 11.05%. Roivant Sciences has a consensus price target of $33.59, indicating a potential upside of 11.82%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A

Summary

Roivant Sciences beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Immunovant compare to Insmed?

Immunovant (NASDAQ:IMVT) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

In the previous week, Insmed had 21 more articles in the media than Immunovant. MarketBeat recorded 25 mentions for Insmed and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Insmed's score of 1.22 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	18 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A

47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immunovant currently has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Insmed has a consensus target price of $212.50, suggesting a potential upside of 117.17%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Insmed	-144.44%	-130.11%	-51.57%

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Summary

Insmed beats Immunovant on 9 of the 16 factors compared between the two stocks.

How does Immunovant compare to Moderna?

Immunovant (NASDAQ:IMVT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immunovant currently has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Moderna has a consensus target price of $36.60, suggesting a potential downside of 26.67%. Given Immunovant's stronger consensus rating and higher possible upside, research analysts clearly believe Immunovant is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Moderna	-143.55%	-26.64%	-19.32%

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

In the previous week, Moderna had 15 more articles in the media than Immunovant. MarketBeat recorded 19 mentions for Moderna and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Moderna's score of 0.57 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Moderna	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Immunovant has higher earnings, but lower revenue than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Moderna	$1.94B	10.19	-$2.82B	-$8.15	N/A

Summary

Moderna beats Immunovant on 8 of the 15 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.90B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-12.09	20.00	24.22	24.42
Price / Sales	N/A	305.69	511.60	109.90
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	8.02	8.32	10.65	6.82
Net Income	-$505.61M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.16%	1.84%	0.58%	1.17%
1 Month Performance	22.30%	-0.04%	1.54%	3.16%
1 Year Performance	114.69%	44.82%	25.40%	30.58%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	3.006 of 5 stars	$33.62 flat	$37.33 +11.0%	+114.7%	$6.90B	N/A	N/A	120	Positive News
SLNO Soleno Therapeutics	3.8747 of 5 stars	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
BNTX BioNTech	4.5676 of 5 stars	$85.50 -2.9%	$129.56 +51.5%	-15.0%	$22.27B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.2976 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+165.4%	$20.56B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4231 of 5 stars	$94.17 -0.1%	$212.50 +125.7%	-0.9%	$20.42B	$606.42M	N/A	1,664	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. SLNO, BNTX, ROIV, INSM, and MRNA

How does Immunovant compare to Soleno Therapeutics?

Summary

How does Immunovant compare to BioNTech?

Summary

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to Insmed?

Summary

How does Immunovant compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. SLNO, BNTX, ROIV, INSM, and MRNA

How does Immunovant compare to Soleno Therapeutics?

Do insiders and institutionals hold more shares of IMVT or SLNO?

Do analysts prefer IMVT or SLNO?

Which has higher valuation and earnings, IMVT or SLNO?

Does the media refer more to IMVT or SLNO?

Is IMVT or SLNO more profitable?

Which has more risk & volatility, IMVT or SLNO?

Summary

How does Immunovant compare to BioNTech?

Which has preferable earnings & valuation, IMVT or BNTX?

Does the media favor IMVT or BNTX?

Is IMVT or BNTX more profitable?

Which has more volatility and risk, IMVT or BNTX?

Do analysts recommend IMVT or BNTX?

Do insiders and institutionals believe in IMVT or BNTX?

Summary

How does Immunovant compare to Roivant Sciences?

Which has more risk and volatility, IMVT or ROIV?

Does the media favor IMVT or ROIV?

Do insiders and institutionals believe in IMVT or ROIV?

Is IMVT or ROIV more profitable?

Do analysts recommend IMVT or ROIV?

Which has better earnings and valuation, IMVT or ROIV?

Summary

How does Immunovant compare to Insmed?

Does the media refer more to IMVT or INSM?

Which has preferable earnings and valuation, IMVT or INSM?

Do insiders & institutionals have more ownership in IMVT or INSM?

Do analysts recommend IMVT or INSM?

Is IMVT or INSM more profitable?

Which has more risk & volatility, IMVT or INSM?

Summary

How does Immunovant compare to Moderna?

Do institutionals and insiders have more ownership in IMVT or MRNA?

Do analysts prefer IMVT or MRNA?

Is IMVT or MRNA more profitable?

Which has more volatility & risk, IMVT or MRNA?

Does the media favor IMVT or MRNA?

Which has stronger earnings & valuation, IMVT or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools